Background : Carbapenem-resistant (CR) Enterobacterales are established causes of serious healthcare-associated infections. Development of new β-lactam/β-lactamase inhibitors was a breakthrough, but effective antibiotic treatment for metallo-β-lactamase (MBL) producers remained an unmet need. Ceftazidime-avibactam (CZA) combination with aztreonam (ATM) is an emerging option to combat these bugs. A...